However, despite the global trends, zooming in on individual PAX3-FOXO1 target genes revealed variability of response (Figure 3e), mirroring the variability of tumor growth reduction in the BMS-986158-treated PDX tumors. The gene discussed is FOXO1; the disease is neoplasm.